Carbamates

BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type

Retrieved on: 
Wednesday, August 4, 2021
Organic chemistry, Chemistry, Carbonyl compounds, Carbamates, Taxanes, Diketopiperazines, Imidazoles, Plinabulin, Docetaxel

Plinabulin is a first-in-class, selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen presenting cell (APC) inducer.

Key Points: 
  • Plinabulin is a first-in-class, selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen presenting cell (APC) inducer.
  • The DUBLIN-3 Phase 3 trial is a randomized, single blind to patients, active controlled, global trial that enrolled 559 patients in 2nd and 3rd line NSCLC, EGFR wild type, with measurable lung lesion.
  • Plinabulin in combination with docetaxel (DP) showed statistically significant improvements compared to docetaxel alone (D) with topline data summarized below for ITT population (DP: n=278; D: n=281).
  • Now that checkpoint inhibitor immunotherapy has moved into first line, there is a vacuum in this indication, where treatment is heavily centered around docetaxel.

FDA Approves First Oral Blood Thinning Medication for Children

Retrieved on: 
Monday, June 21, 2021
Chemical compounds, Organic compounds, Functional groups, Boehringer Ingelheim, Benzimidazoles, Carbamates, Dabigatran

Pradaxa is the first FDA-approved blood thinning medication that children can take by mouth; the only other approved blood thinning medication for children is given by injection.

Key Points: 
  • Pradaxa is the first FDA-approved blood thinning medication that children can take by mouth; the only other approved blood thinning medication for children is given by injection.
  • "With today's approval of Pradaxa, pediatric patients have another therapeutic option to treat and prevent potentially deadly blood clots."
  • Blood clots can be a serious problem in children as well as adults.
  • The primary endpoints of the study were recurrence of blood clots, major and minor bleeding events, and death (both overall and related to blood clots).

Sunshine Biopharma Mice Study for COVID-19 Treatment Progressing as Planned

Retrieved on: 
Wednesday, June 9, 2021
Protease inhibitor, Antiviral drugs, Draft:Sunshine Biopharma, Carbamates, Organofluorides, HIV protease inhibitors

The study is assessing the efficacy of two protease inhibitors in preventing transgenic mice challenged with SARS-CoV-2 from progressing to illness and death.

Key Points: 
  • The study is assessing the efficacy of two protease inhibitors in preventing transgenic mice challenged with SARS-CoV-2 from progressing to illness and death.
  • Sunshine Biopharmas protease inhibitor treatment is anticipated to be orally available making it possible for the treatment to be in tablet form which can be taken at home.
  • We are moving the project forward as fast as possible, albeit within the constraints of science, said Dr. Steve Slilaty, CEO of Sunshine Biopharma.
  • In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound.

Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral Hepatitis B Virus RNA Destabilizer, at the International Liver Congress™ 2021 Sponsored by the European Association for the Study of the Liver

Retrieved on: 
Thursday, June 3, 2021
Other Health, Research, General Health, Pharmaceutical, Oncology, Infectious diseases, Clinical trials, Science, Biotechnology, FDA, Other Science, Health, Chemical compounds, Organic compounds, Chemistry, Carbamates, Healthcare-associated infections, Glecaprevir/pibrentasvir, Infectious causes of cancer, Glecaprevir, Hepatitis C, AbbVie, Human metapneumovirus, Pibrentasvir

Enantas research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).

Key Points: 
  • Enantas research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).
  • Enanta is also conducting research in SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).
  • Enantas research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.
  • Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir).

AB Science communicates results from Phase 3 study evaluating masitinib in prostate cancer

Retrieved on: 
Wednesday, May 26, 2021
Carbonyl compounds, Drugs, Chemical compounds, Carbamates, Taxanes, MCRPC, Masitinib, Prostate cancer, Docetaxel

AB Science SA (Euronext FR0010557264 AB) communicated the results from phase 3 study evaluating masitinib in prostate cancer during the webcast that was held on May 25, 2021.

Key Points: 
  • AB Science SA (Euronext FR0010557264 AB) communicated the results from phase 3 study evaluating masitinib in prostate cancer during the webcast that was held on May 25, 2021.
  • The development program in prostate cancer is comprised of AB07004 phase 1/2 proof of concept study (n=34 pts), which supported the combination of masitinib with docetaxel in mCRPC, and AB12003 phase 3 study also in mCRPC patients.
  • Study AB12003 was an international (16 countries), multicenter (67 sites), randomized, double blind, placebo-controlled, 2-parallel group, phase 3 study in mCRPC patients eligible to chemotherapy.
  • A new patent was filed based on results from study AB12003, which would permit AB Science to retain exclusive rights on the use of masitinib in Prostate cancer until 2042.

Albendazole Market by Target Pathogen, End-use and Distribution Channel - Global Forecast up to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 25, 2021
Health, Pharmaceutical, Articles, Albendazole, Anthelmintics, Benzimidazoles, Carbamates, Thioethers, Online pharmacy, Distribution, Economy, Industry economics)

The "Albendazole Market based on Target Pathogen, End-use and Distribution Channel and Geography - Global Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Albendazole Market based on Target Pathogen, End-use and Distribution Channel and Geography - Global Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Albendazole Market is projected to grow at the rate of 7.4% CAGR by 2026.
  • On the other hand, the negative effects of albendazole drugs are likely to hamper the albendazole market growth potential.
  • Online pharmacies are the significant distribution channel in the albendazole market due to the rising online purchases and the availability of various drugs in online pharmacies.

Claritin® Launches The Outsideologist Project - A Multi-Year Initiative Encouraging Children To Spend Time Outdoors

Retrieved on: 
Wednesday, May 12, 2021
Chemical compounds, Drugs, Organic compounds, Carbamates, Chloroarenes, Loratadine, Piperidines

b'WHIPPANY, N.J., May 11, 2021 /PRNewswire/ -- Today, Claritin , the #1 doctor recommended allergy OTC brand, announced the launch of The Outsideologist Project, a new, multi-year initiative aimed at encouraging children to spend more time outdoors.

Key Points: 
  • b'WHIPPANY, N.J., May 11, 2021 /PRNewswire/ -- Today, Claritin , the #1 doctor recommended allergy OTC brand, announced the launch of The Outsideologist Project, a new, multi-year initiative aimed at encouraging children to spend more time outdoors.
  • "Time outside is critical for our health and wellbeing, and I look forward to helping other families foster a deeper appreciation for the outdoors.
  • "That is why Claritin launched The Outsideologist Project to help families across the country instill in their kids a lifelong love of the outdoors and better everyday health.
  • "\nFor additional information about The Outsideologist Project or Claritin, visit www.Claritin.com and our social channels.

Claritin® Launches The Outsideologist Project - A Multi-Year Initiative Encouraging Children To Spend Time Outdoors

Retrieved on: 
Tuesday, May 11, 2021
Chemical compounds, Drugs, Organic compounds, Carbamates, Chloroarenes, Loratadine, Piperidines

b'WHIPPANY, N.J., May 11, 2021 /PRNewswire/ -- Today, Claritin , the #1 doctor recommended allergy OTC brand, announced the launch of The Outsideologist Project, a new, multi-year initiative aimed at encouraging children to spend more time outdoors.

Key Points: 
  • b'WHIPPANY, N.J., May 11, 2021 /PRNewswire/ -- Today, Claritin , the #1 doctor recommended allergy OTC brand, announced the launch of The Outsideologist Project, a new, multi-year initiative aimed at encouraging children to spend more time outdoors.
  • "Time outside is critical for our health and wellbeing, and I look forward to helping other families foster a deeper appreciation for the outdoors.
  • "That is why Claritin launched The Outsideologist Project to help families across the country instill in their kids a lifelong love of the outdoors and better everyday health.
  • "\nFor additional information about The Outsideologist Project or Claritin, visit www.Claritin.com and our social channels.

Enanta Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Tuesday, May 11, 2021
Research, Infectious diseases, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Chemical compounds, Organic compounds, Chemistry, Carbamates, Healthcare-associated infections, Pneumoviridae, Glecaprevir/pibrentasvir, Glecaprevir, Hepatitis C, Pibrentasvir, Human metapneumovirus, AbbVie

Enanta\xe2\x80\x99s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).

Key Points: 
  • Enanta\xe2\x80\x99s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).
  • Enanta is also conducting research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).\nEnanta\xe2\x80\x99s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.
  • Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET\xc2\xae (U.S.) and MAVIRET\xc2\xae (ex-U.S.) (glecaprevir/pibrentasvir).
  • Please visit www.enanta.com for more information.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210511005247/en/\n'

AB Science today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint

Retrieved on: 
Thursday, April 29, 2021
Carbonyl compounds, Anatomy, Branches of biology, Prostate cancer, Carbamates, Taxanes, MCRPC, Docetaxel, Prostate, Cabazitaxel, Enzalutamide

The study aimed to compare the efficacy and safety of masitinib (6.0 mg/kg/day) in combination with docetaxel versus placebo in combination with docetaxel.

Key Points: 
  • The study aimed to compare the efficacy and safety of masitinib (6.0 mg/kg/day) in combination with docetaxel versus placebo in combination with docetaxel.
  • Docetaxel was combined with prednisone.\nThe target patient population consisted of adult males who had progressed to develop metastatic castrate resistant prostate cancer (mCRPC) after castration treatment (i.e.
  • The estimated prevalence of people living with prostate cancer is 113 per 100,000 [2], with approximately 15% of the patients having metastatic castrate-resistant prostate cancer (mCRPC) eligible to chemotherapy [3].
  • AB Science disclaims any obligation\xc2\xa0or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq.